Another post from the 50th meeting of the American Society of Clinical Oncology (ASCO)(earlier post). Extremely promising results were shown for a new combination immunotherapy for melanoma (ipilimumab (Yervoy, Bristol-Myers Squibb), investigational antibody nivolumab (Bristol-Myers Squibb)). Melanoma has been a tricky, hard to treat cancer for researchers, so this small study is truly remarkable.
“Concurrent use of the 2 immune-checkpoint blockade agents has produced the “unprecedented” overall survival rates for metastatic melanoma of 85% at 1 year and 79% at 2 years in a phase 1 study, said lead author Mario Sznol, MD, from the Yale University School of Medicine in New Haven, Connecticut.
The median overall survival for the 53 patients treated in the study was 40 months — also unprecedented. “That’s amazing,” Dr. Sznol told Medscape Medical News.”